The $40 million Department of Defense research program into restoring memory will use NeuroPace's implantable neurostimulator, a move that the company said could help it expand the product's indications beyond epilepsy.
Catheter-directed thrombolysis (CDT) has been used in an effort to reduce the incidence of post-thrombotic syndrome in deep vein thrombosis. But a newly published observational study suggests that not only is catheter use ineffective at preventing post-thrombotic syndrome, but it is actually associated with higher rates of adverse events.
With more than 15 510(k)s cleared in 2014, spinal fusion devices rank among the leaders. But new entrants such as Titan Spine and Expanding Orthopedics are entering the market just as insurers are beginning to crack down on reimbursement for the invasive procedure that costs an average of $27,600 per hospital stay.
Wisconsin's Titan Spine announced today that it received 510(k) clearance from the FDA for its Endoskeleton TL System implant for spinal fusion.
Orthopedic specialist Smith & Nephew will market Blue Belt's surgical knee system in a worldwide agreement that could help breathe fresh life into Smith & Nephew's flagging knee implant revenue growth. The partnership with Smith & Nephew is the startup's first major distribution deal.
Soon, there will be a device to cure some forgetfulness if the Department of Defense's four-year grant of up to $40 million succeeds in fostering implants and electronic interfaces that diagnose and treat memory loss due to traumatic brain injury.
Gold nanoparticles help prevent the formation of antibiotic resistant biofilm on the surface of orthopedic implants, researchers at the Shanghai Institute of Ceramics discovered.
In a move that could draw attention from the world's top cardiac devicemakers, researchers in Korea have developed a self-powered artificial cardiac pacemaker that operates without battery power.
The FDA has told Boston Scientific its Watchman implant designed to help prevent strokes in atrial fibrillation patients will have to face a third advisory panel before gaining approval.
PowerVision roped in $30 million in Series D financing to support development of its innovative fluid-based intraocular lens implant.